115 related articles for article (PubMed ID: 17768130)
1. Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
Götze KS; Hoffmann D; Schätzl HM; Peschel C; Fend F; Decker T
Haematologica; 2007 Sep; 92(9):1282-3. PubMed ID: 17768130
[TBL] [Abstract][Full Text] [Related]
2. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation.
Jindra P; Koza V; Boudová L; Vozobulová V; Cerná K; Karas M; Lysák D; Svojgrová M
Bone Marrow Transplant; 2003 May; 31(10):951-2. PubMed ID: 12748677
[No Abstract] [Full Text] [Related]
4. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
Abruzzo LV; Rosales CM; Medeiros LJ; Vega F; Luthra R; Manning JT; Keating MJ; Jones D
Am J Surg Pathol; 2002 May; 26(5):630-6. PubMed ID: 11979093
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia.
Compérat E; Delmer A; Le Tourneau A; Molina TJ; Diebold J; Audouin J
Arch Pathol Lab Med; 2006 Aug; 130(8):1227-30. PubMed ID: 16879030
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-associated lymphoproliferative disorder developed after anti-thymocyte globulin therapy in a patient with bone marrow failure associated with T-cell large granular lymphocytic leukemia.
Sumi M; Watanabe M; Sato K; Shimizu I; Ueki T; Akahane D; Ueno M; Ichikawa N; Asano N; Kobayashi H
Rinsho Ketsueki; 2011 Nov; 52(11):1782-7. PubMed ID: 22185802
[TBL] [Abstract][Full Text] [Related]
7. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications.
Subramaniam K; Cherian M; Jain S; Latimer M; Corbett M; D'Rozario J; Pavli P
Intern Med J; 2013 Dec; 43(12):1339-42. PubMed ID: 24330365
[TBL] [Abstract][Full Text] [Related]
8. First report of Epstein-Barr virus lymphoproliferative disease after cord blood transplantation.
Sirvent N; Reviron D; de Lamballerie X; Michel G
Bone Marrow Transplant; 2000 Jan; 25(1):120-1. PubMed ID: 10654028
[No Abstract] [Full Text] [Related]
9. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders.
Boratyńska M; Smolska D
Transpl Int; 2008 Jun; 21(6):605-8. PubMed ID: 18282244
[No Abstract] [Full Text] [Related]
10. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
García-Barchino MJ; Sarasquete ME; Panizo C; Morscio J; Martinez A; Alcoceba M; Fresquet V; Gonzalez-Farre B; Paiva B; Young KH; Robles EF; Roa S; Celay J; Larrayoz M; Rossi D; Gaidano G; Montes-Moreno S; Piris MA; Balanzategui A; Jimenez C; Rodriguez I; Calasanz MJ; Larrayoz MJ; Segura V; Garcia-Muñoz R; Rabasa MP; Yi S; Li J; Zhang M; Xu-Monette ZY; Puig-Moron N; Orfao A; Böttcher S; Hernandez-Rivas JM; Miguel JS; Prosper F; Tousseyn T; Sagaert X; Gonzalez M; Martinez-Climent JA
J Pathol; 2018 May; 245(1):61-73. PubMed ID: 29464716
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease.
Rath J; Geisler C; Christiansen CB; Hastrup N; Madsen HO; Andersen MK; Pedersen LB; Jurlander J
Haematologica; 2008 Sep; 93(9):1424-6. PubMed ID: 18641020
[No Abstract] [Full Text] [Related]
12. Posttransplantation lymphoproliferative disorder: case report.
Perkowska A; Durlik M; Suleiman W; Maryniak R; Gaciong Z; Juskowa J; Rostamzadeh Khameneh Z; Szmidt J; Lao M
Transplant Proc; 2000 Sep; 32(6):1387-8. PubMed ID: 10995990
[No Abstract] [Full Text] [Related]
13. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
14. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine.
Mercadal S; Martinez A; Nomdedeu B; Rozman M; Gaya A; Salamero O; Campo E
Eur J Haematol; 2006 Nov; 77(5):442-4. PubMed ID: 17044837
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
18. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Orlandi EM; Baldanti F; Citro A; Pochintesta L; Gatti M; Lazzarino M
Haematologica; 2008 Nov; 93(11):1758-60. PubMed ID: 18790800
[No Abstract] [Full Text] [Related]
19. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis.
Thornton PD; Bellas C; Santon A; Shah G; Pocock C; Wotherspoon AC; Matutes E; Catovsky D
Leuk Res; 2005 Apr; 29(4):389-95. PubMed ID: 15725472
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
